Principal Financial Group’s Ligand Pharmaceuticals LGND Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$31M Buy
97,971
+2,255
+2% +$531K 0.02% 739
2026
Q1
$19.1M Buy
95,716
+1,886
+2% +$373K 0.01% 958
2025
Q4
$17.7M Sell
93,830
-772
-0.8% -$148K 0.01% 969
2025
Q3
$16.8M Sell
94,602
-7,210
-7% -$1.07M 0.01% 969
2025
Q2
$11.6M Sell
101,812
-1,062
-1% -$114K 0.01% 1172
2025
Q1
$10.8M Buy
102,874
+3,284
+3% +$371K 0.01% 1212
2024
Q4
$10.7M Buy
99,590
+6,382
+7% +$721K 0.01% 1262
2024
Q3
$9.33M Buy
93,208
+4,439
+5% +$447K 0.01% 1319
2024
Q2
$7.48M Sell
88,769
-3,355
-4% -$267K ﹤0.01% 1407
2024
Q1
$6.73M Sell
92,124
-686
-0.7% -$50.6K ﹤0.01% 1478
2023
Q4
$6.63M Sell
92,810
-1,268
-1% -$74.8K ﹤0.01% 1459
2023
Q3
$5.64M Sell
94,078
-3,982
-4% -$262K ﹤0.01% 1491
2023
Q2
$7.07M Sell
98,060
-3,610
-4% -$271K ﹤0.01% 1406
2023
Q1
$7.48M Sell
101,670
-1,899
-2% -$135K 0.01% 1390
2022
Q4
$6.92M Sell
103,569
-60,456
-37% -$3.93M 0.01% 1419
2022
Q3
$8.81M Sell
164,025
-18,719
-10% -$1.1M 0.01% 1257
2022
Q2
$10.2M Sell
182,744
-13,489
-7% -$765K 0.01% 1242
2022
Q1
$13.8M Sell
196,233
-13,694
-7% -$994K 0.01% 1186
2021
Q4
$20.2M Sell
209,927
-55,708
-21% -$5.15M 0.01% 942
2021
Q3
$23.1M Buy
265,635
+89,629
+51% +$6.93M 0.02% 826
2021
Q2
$14.4M Buy
176,006
+14,089
+9% +$1.17M 0.01% 1220
2021
Q1
$15.4M Buy
161,917
+19,999
+14% +$1.89M 0.01% 1132
2020
Q4
$8.8M Sell
141,918
-16,888
-11% -$963K 0.01% 1311
2020
Q3
$9.44M Buy
158,806
+32,227
+25% +$2.2M 0.01% 1112
2020
Q2
$8.83M Buy
126,579
+43,616
+53% +$2.77M 0.01% 1129
2020
Q1
$3.76M Sell
82,963
-41,076
-33% -$2.33M ﹤0.01% 1398
2019
Q4
$8.07M Sell
124,039
-5,459
-4% -$365K 0.01% 1354
2019
Q3
$8.04M Sell
129,498
-6,484
-5% -$407K 0.01% 1323
2019
Q2
$9.68M Sell
135,982
-10,289
-7% -$758K 0.01% 1240
2019
Q1
$11.5M Sell
146,271
-4,804
-3% -$364K 0.01% 1152
2018
Q4
$12.8M Sell
151,075
-151,334
-50% -$16.1M 0.01% 1012
2018
Q3
$51.8M Buy
302,409
+8,861
+3% +$1.34M 0.05% 410
2018
Q2
$37.9M Buy
293,548
+831
+0.3% +$92.7K 0.03% 486
2018
Q1
$30.2M Buy
292,717
+8,473
+3% +$838K 0.03% 569
2017
Q4
$24.3M Buy
284,244
+25,204
+10% +$2.18M 0.02% 692
2017
Q3
$22M Buy
259,040
+19,879
+8% +$1.57M 0.02% 718
2017
Q2
$18.1M Sell
239,161
-20,491
-8% -$1.43M 0.02% 827
2017
Q1
$17.1M Buy
259,652
+8,044
+3% +$529K 0.02% 824
2016
Q4
$15.9M Buy
251,608
+21,023
+9% +$1.33M 0.02% 847
2016
Q3
$14.7M Buy
230,585
+11,271
+5% +$828K 0.02% 855
2016
Q2
$16.3M Buy
219,314
+15,087
+7% +$1.12M 0.02% 741
2016
Q1
$13.6M Buy
204,227
+7,900
+4% +$480K 0.02% 796
2015
Q4
$13.3M Buy
196,327
+9,148
+5% +$565K 0.02% 772
2015
Q3
$10M Buy
187,179
+7,571
+4% +$459K 0.02% 922
2015
Q2
$11.3M Sell
179,608
-3,382
-2% -$185K 0.02% 915
2015
Q1
$8.8M Sell
182,990
-61
-0% -$2.34K 0.01% 1063
2014
Q4
$6.08M Sell
183,051
-6,242
-3% -$203K 0.01% 1283
2014
Q3
$5.55M Sell
189,293
-19,865
-9% -$659K 0.01% 1290
2014
Q2
$8.13M Buy
209,158
+8
+0% +$325 0.01% 1073
2014
Q1
$8.78M Buy
209,150
+9,310
+5% +$388K 0.02% 995
2013
Q4
$6.56M Buy
199,840
+190,935
+2,144% +$6.22M 0.01% 1172
2013
Q3
$240K Sell
8,905
-583
-6% -$16.4K ﹤0.01% 2041
2013
Q2
$221K Buy
+9,488
New +$171K ﹤0.01% 2043

Other funds holding LGND

Principal Financial Group's LGND Position: Q2 2026 in Review

Principal Financial Group increased its Ligand Pharmaceuticals (LGND) stake by 2.4% in Q2 2026, buying an estimated $531K and bringing the position to 97,971 shares worth $31M. The position accounts for 0.02% of the portfolio, ranked #739.

Principal Financial Group first reported a position in LGND in Q2 2013 and has held it in 53 quarters since. The position peaked at $51.8M in Q3 2018. 414 funds tracked by Wall St. Rank hold LGND as of Q2 2026.

  • Principal Financial Group held 97,971 shares of Ligand Pharmaceuticals worth $31M as of Q2 2026.
  • Principal Financial Group bought 2,255 Ligand Pharmaceuticals shares in Q2 2026, an estimated $531K.
  • Ligand Pharmaceuticals made up 0.02% of Principal Financial Group's portfolio in Q2 2026, its #739 holding.
  • Principal Financial Group first reported a position in Ligand Pharmaceuticals in Q2 2013 and has held it in 53 quarters since.
  • Principal Financial Group's Ligand Pharmaceuticals position peaked at $51.8M in Q3 2018.
  • 414 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.

Based on Principal Financial Group's 13F filing for Q2 2026, filed 4 Aug 2026.